ATG-032 / Antengene - LARVOL DELTA

Antengene Announces Interim 2022 Financial Results and Provides Corporate Update (PRNewswire) - "Internal Discovery Program: (i) IND Candidates for the Remainder of 2022: ATG-022 (Claudin 18.2 antibody-drug conjugate). IND filing expected in 2H2022; (ii) 2023 Potential IND/CTA Filings: ATG-031 (anti-CD24 monoclonal antibody); (iii) Early Stage, IND Track Programs: ATG-027 (B7H3/PD-L1 bispecific antibody), ATG-032 (LILRB antibody) and ATG-041 (Axl-Mer inhibitor)."

IND • Oncology

Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates (PRNewswire) - "Planning 2 INDs per Year (Antengene has global rights): (i) 2022 IND Candidates: Antengene plans to submit an IND application for ATG-018 (ATR inhibitor) in H1:22. In addition, preclinical studies are also underway to support IND/CTA applications of ATG-022 (Claudin 18.2 antibody-drug conjugate) in 2022; (ii) 2023 Potential IND/CTA Filings: ATG-031 (CD24 antibody) and ATG-027 (B7H3/PD-L1 bispecific antibody); (iii) Early Stage, IND Track Programs: ATG-032 (LILRB antibody) and ATG-041 (Axl-Mer inhibitor)."

IND • Preclinical • Oncology